Industry
Biotechnology
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Loading...
Open
23.81
Mkt cap
1.4B
Volume
398K
High
24.45
P/E Ratio
-0.64
52-wk high
47.97
Low
23.50
Div yield
N/A
52-wk low
14.62
Portfolio Pulse from
December 17, 2024 | 4:30 pm
Portfolio Pulse from
December 16, 2024 | 7:15 pm
Portfolio Pulse from
December 15, 2024 | 5:15 pm
Portfolio Pulse from
December 13, 2024 | 5:15 pm
Portfolio Pulse from
December 11, 2024 | 7:15 pm
Portfolio Pulse from
December 04, 2024 | 12:30 am
Portfolio Pulse from
December 02, 2024 | 10:15 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.